Summary
Edwards Lifesciences Corporation (EW) filed an 8-K report on February 4, 2010, to announce its financial results for the fourth quarter and full year 2009. This report primarily serves as a vehicle to furnish a press release detailing these financial outcomes. Investors should review the attached press release (Exhibit 99.1) for specific details on revenue, profitability, and operational performance for the reported periods. The key takeaway for investors is the official release of 2009 year-end and Q4 financial performance. While the 8-K itself is a procedural filing, the accompanying press release will contain the crucial financial metrics, strategic commentary from management, and likely forward-looking statements that are essential for evaluating the company's health and future prospects. Investors are advised to examine the press release for any significant trends, earnings per share (EPS) figures, and guidance provided by the company.
Key Highlights
- 1The 8-K filing announces Edwards Lifesciences' financial results for the fourth quarter and full year 2009.
- 2The report was filed on February 4, 2010, with the earliest event date being February 3, 2010.
- 3The primary content is a press release, attached as Exhibit 99.1, detailing the financial performance.
- 4This filing is made pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
- 5The press release is not deemed 'filed' for the purposes of the Securities Exchange Act of 1934, but rather furnished.
- 6Thomas M. Abate, Corporate Vice President, Chief Financial Officer and Treasurer, signed the report.
- 7Investors should refer to Exhibit 99.1 for detailed financial results and commentary.